Search Results - Paola Curci

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. <i>Pharmaceuticals</i> 2025, <i>18</i>, 595

    Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Tr... by Nicola Sgherza, Olga Battisti, Paola Curci, Concetta Conticello, Salvatore Palmieri, Daniele Derudas, Candida Germano, Enrica Antonia Martino, Giuseppe Mele, Roberta Della Pepa, Francesca Fazio, Anna Mele, Bernardo Rossini, Giulia Palazzo, Daniela Roccotelli, Simona Rasola, Maria Teresa Petrucci, Domenico Pastore, Giuseppe Tarantini, Fabrizio Pane, Massimo Gentile, Francesco Di Raimondo, Emanuela Resta, Pellegrino Musto

    Published 2025-06-01
    Get full text
    Article

    Save to List
    Saved in:
  2. 2
    Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial

    Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial by Sara Bringhen, Lorenzo Cani, Nicola Giuliani, Silvia Mangiacavalli, Giulia Benevolo, Elisabetta Antonioli, Renato Zambello, Roberto Ria, Iolanda Donatella Vincelli, Sonia Ronconi, Sonia More, Antonietta Pia Falcone, Alessandro Allegra, Mattia D'Agostino, Andrea Evangelista, Andrea Capra, Elisa Sciorsci, Paola Curci, Patrizia Tosi, Anna Marina Liberati, Anna Maria Cafro, Angelo Belotti, Francesca Patriarca, Donato Mannina, Katia Mancuso, Francesco Cattel, Giovannino Ciccone, Benedetto Bruno, Mario Boccadoro, Alessandra Larocca

    Published 2025-07-01
    Get full text
    Article

    Save to List
    Saved in:

Search Tools: